Skip to content

CG Oncology CGON Investment Proceeds

Investment Proceeds at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$79.38M+1,384%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$177.29M+10.4%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$175.5K
Biogen logo
BiogenBIIB
$500K
Incyte logo
IncyteINCY
$0-100%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$133.86M+0.8%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%
Enterprise value$5.36B+212%
P/S1,062.4×-1,596×

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's investment proceeds?
CG Oncology (CGON) reported investment proceeds of $252.85M in Q1 2026.
How has CG Oncology's investment proceeds changed year-over-year?
CG Oncology's investment proceeds increased by 26.3% year-over-year, from $200.14M to $252.85M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.